Literature DB >> 27836787

Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition.

Noriyuki Yamada1, Tamotsu Sugai2, Makoto Eizuka1, Koudai Tsuchida1, Ryo Sugimoto1, Yoshiharu Mue1, Masamichi Suzuki1, Mitsumasa Osakabe1, Noriyuki Uesugi1, Kazuyuki Ishida1, Kouki Otsuka3, Takayuki Matsumoto4.   

Abstract

Tumor budding is thought to reflect the epithelial-mesenchymal transition (EMT). However, the molecular mechanism linking tumor buds and the EMT remains unclear. Here, we examined the induction of tumor budding and EMT and their association with EMT-related proteins (ZEB1, TWIST, SNAIL, and SLUG) in colorectal cancer (CRC). Immunohistochemical expression of pan-cytokeratin was examined for identification of tumor budding in 101 CRCs. Grading of tumor budding was classified into low- and high-grade groups. Tissue microarray was conducted to identify tumor budding sites. The expression of E-cadherin, ZEB1, TWIST, SNAIL, and SLUG was examined in areas of tumor budding and the surrounding tumor stroma using a double-immunostaining method. Specifically, pan-cytokeratin and EMT-related proteins were assessed by double immunostaining. Low or no expression of E-cadherin was found in areas of tumor budding. Moreover, ZEB1, TWIST, SNAIL, and SLUG were not expressed in regions of tumor budding. However, the expression level of ZEB1 in the stromal cells surrounding tumor budding was significantly more frequent than that of TWIST, SNAI, and SLUG. In addition, the expression of EMT-related proteins in surrounding stromal cells was significantly greater in areas of high-grade tumor budding than in low-grade areas. Our present results suggest that EMT-related proteins play a minor role in forming tumor buds. In addition, our findings suggest the existence of subtypes of stromal cells in CRC with phenotypical and functional heterogeneity.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Epithelial-mesenchymal transition; TWIST; Tumor budding; ZEB1

Mesh:

Substances:

Year:  2016        PMID: 27836787     DOI: 10.1016/j.humpath.2016.10.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  22 in total

1.  Tumor budding is an adverse prognostic marker in intestinal-type sinonasal adenocarcinoma and seems to be unrelated to epithelial-mesenchymal transition.

Authors:  Valeria Maffeis; Rocco Cappellesso; Francesca Galuppini; Vincenza Guzzardo; Alessia Zanon; Diego Cazzador; Enzo Emanuelli; Laura Ventura; Alessandro Martini; Ambrogio Fassina
Journal:  Virchows Arch       Date:  2020-01-24       Impact factor: 4.064

Review 2.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

3.  Continuous formation of small clusters with LGR5-positive cells contributes to tumor growth in a colorectal cancer xenograft model.

Authors:  Masaki Yamazaki; Atsuhiko Kato; Eiji Oki; Yoko Zaitsu; Chie Kato; Kiyotaka Nakano; Miho Nakamura; Takuya Sakomura; Shigeto Kawai; Etsuko Fujii; Noriaki Sawada; Takeshi Watanabe; Hiroshi Saeki; Masami Suzuki
Journal:  Lab Invest       Date:  2020-07-29       Impact factor: 5.662

4.  Tumor Budding as a Predictive Marker of Relapse and Survival in Patients With Stage II Colon Cancer.

Authors:  Kazuyuki Saito; Takashi Okuyama; Shunya Miyazaki; Haruka Oi; Takashi Mitsui; Takuji Noro; Emiko Takeshita; Yuko Ono; Taizen Urahashi; Hidehiro Tajima; Hideyuki Yoshitomi
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

Review 5.  [Three-dimensional reconstruction of solid tumors : Morphological evidence for tumor heterogeneity].

Authors:  K Enderle-Ammour; U Wellner; E Kocsmar; A Kiss; G Lotz; A Csanadi; M Bader; O Schilling; M Werner; P Bronsert
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

6.  E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models.

Authors:  Jarle Bruun; Peter W Eide; Christian Holst Bergsland; Oscar Bruck; Aud Svindland; Mariliina Arjama; Katja Välimäki; Merete Bjørnslett; Marianne G Guren; Olli Kallioniemi; Arild Nesbakken; Ragnhild A Lothe; Teijo Pellinen
Journal:  Mol Oncol       Date:  2021-12-26       Impact factor: 7.449

7.  MicroRNA-200b is downregulated in colon cancer budding cells.

Authors:  Kirsten Nguyen Knudsen; Jan Lindebjerg; Boye Schnack Nielsen; Torben Frøstrup Hansen; Flemming Brandt Sørensen
Journal:  PLoS One       Date:  2017-05-26       Impact factor: 3.240

Review 8.  Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.

Authors:  Cristina Díaz Del Arco; Luis Ortega Medina; Lourdes Estrada Muñoz; Soledad García Gómez de Las Heras; Mª Jesús Fernández Aceñero
Journal:  Histol Histopathol       Date:  2021-02-10       Impact factor: 2.303

9.  Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins.

Authors:  Bijiao Zhou; Shumin Zong; Weilong Zhong; Yixuan Tian; Lumeng Wang; Qian Zhang; Renya Zhang; Lei Li; Wei Wang; Jianmin Zhao; Xin Chen; Yaju Feng; Binghui Zhai; Tao Sun; Yanrong Liu
Journal:  Oncogene       Date:  2019-11-01       Impact factor: 8.756

10.  Expression Profile and Prognostic Significance of EPHB3 in Colorectal Cancer.

Authors:  Bo Gun Jang; Hye Sung Kim; Jeong Mo Bae; Woo Ho Kim; Chang Lim Hyun; Gyeong Hoon Kang
Journal:  Biomolecules       Date:  2020-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.